672745662	672745662	CD	B-NP	O
|	|	NN	I-NP	O
AMC	AMC	NN	I-NP	O
|	|	NN	I-NP	O
96063741	96063741	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
4968794	4968794	CD	B-NP	O
|	|	CC	I-NP	O
5/18/2006	5/18/2006	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	O
CONGESTIVE	CONGESTIVE	NNP	I-NP	O
HEART	HEART	NNP	I-NP	O
FAILURE	FAILURE	NNP	I-NP	O
,	,	,	O	O
ATRIAL	ATRIAL	NNP	B-NP	O
FIBRILLATION	FIBRILLATION	NNP	I-NP	O
|	|	NNP	I-NP	O
Signed	Signed	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
8/28/2006	8/28/2006	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Signed	Signed	NNP	B-NP	O
Discharge	Discharge	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
1/6/2006	1/6/2006	CD	B-NP	O
ATTENDING	ATTENDING	NN	I-NP	O
:	:	:	O	O
COFFELL	COFFELL	NN	B-NP	O
,	,	,	O	O
TOMAS	TOMAS	NNP	B-NP	O
MD	MD	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
OF	OF	IN	B-PP	O
PRESENT	PRESENT	NNP	B-NP	O
ILLNESS	ILLNESS	NNP	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
an	an	DT	B-NP	O
elective	elective	JJ	I-NP	O
right	right	JJ	I-NP	O
heart	heart	NN	I-NP	O
catheterization	catheterization	NN	I-NP	O
and	and	CC	I-NP	O
reassessment	reassessment	NN	I-NP	O
of	of	IN	B-PP	O
refractory	refractory	JJ	B-NP	O
CHF	CHF	NN	I-NP	O
and	and	CC	O	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
62-year-old	62-year-old	JJ	I-NP	O
man	man	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
nonischemic	nonischemic	JJ	B-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	O
of	of	IN	B-PP	O
30	30	CD	B-NP	O
%	%	NN	I-NP	O
who	who	WP	B-NP	O
was	be	VBD	B-VP	O
diagnosed	diagnose	VBN	I-VP	O
about	about	IN	B-NP	O
ten	ten	CD	I-NP	O
years	year	NNS	I-NP	O
ago	ago	RB	B-ADVP	O
and	and	CC	O	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
stable	stable	JJ	B-ADJP	O
with	with	IN	B-PP	O
medical	medical	JJ	B-NP	O
management	management	NN	I-NP	O
until	until	IN	B-PP	O
this	this	DT	B-NP	O
past	past	JJ	I-NP	O
year	year	NN	I-NP	O
when	when	WRB	B-ADVP	O
he	he	PRP	B-NP	O
started	start	VBD	B-VP	O
developing	develop	VBG	I-VP	O
worsening	worsen	VBG	B-NP	O
dyspnea	dyspnea	NN	I-NP	O
on	on	IN	B-PP	O
exertion	exertion	NN	B-NP	O
,	,	,	O	O
orthopnea	orthopnea	NN	B-NP	O
,	,	,	O	O
palpitations	palpitation	NNS	B-NP	O
,	,	,	O	O
and	and	CC	O	O
PND	PND	NN	B-NP	B-protein
.	.	.	O	O

His	His	PRP$	B-NP	O
functional	functional	JJ	I-NP	O
status	status	NN	I-NP	O
has	have	VBZ	B-VP	O
declined	decline	VBN	I-VP	O
significantly	significantly	RB	B-ADVP	O
since	since	IN	B-PP	O
then	then	RB	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
11/26	11/26	CD	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
decompensated	decompensate	VBN	B-NP	O
heart	heart	NN	I-NP	O
failure	failure	NN	I-NP	O
and	and	CC	O	O
diuresed	diurese	VBD	B-VP	O
back	back	RB	B-ADVP	O
to	to	TO	B-PP	O
dry	dry	JJ	B-NP	O
weight	weight	NN	I-NP	O
.	.	.	O	O

An	An	DT	B-NP	O
ICD	ICD	NN	I-NP	B-protein
was	be	VBD	B-VP	O
placed	place	VBN	I-VP	O
at	at	IN	B-PP	O
that	that	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

Following	Follow	VBG	B-PP	O
discharge	discharge	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
developed	develop	VBD	B-VP	O
AFib	AFib	NN	B-NP	O
with	with	IN	B-PP	O
rapid	rapid	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
response	response	NN	I-NP	O
and	and	CC	O	O
underwent	undergo	VBD	B-VP	O
DC	DC	NN	B-NP	B-cell_type
cardioversion	cardioversion	NN	I-NP	O
with	with	IN	B-PP	O
Dr.	Dr.	NNP	B-NP	O
Gerry	Gerry	NNP	I-NP	O
Canseco	Canseco	NNP	I-NP	O
however	however	RB	B-ADVP	O
,	,	,	O	O
relapsed	relapse	VBD	B-VP	O
shortly	shortly	RB	B-ADVP	O
,	,	,	O	O
thereafter	thereafter	RB	B-ADVP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
amiodarone	amiodarone	NN	B-NP	O
,	,	,	O	O
but	but	CC	O	O
developed	develop	VBD	B-VP	O
a	a	DT	B-NP	O
question	question	NN	I-NP	O
of	of	IN	B-PP	O
pulmonary	pulmonary	JJ	B-NP	O
toxicity	toxicity	NN	I-NP	O
with	with	IN	B-PP	O
significant	significant	JJ	B-NP	O
dry	dry	JJ	I-NP	O
coughing	coughing	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
continued	continue	VBN	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
in	in	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
with	with	IN	B-PP	O
rapid	rapid	JJ	B-NP	O
ventricular	ventricular	JJ	I-NP	O
response	response	NN	I-NP	O
despite	despite	IN	B-PP	O
maximal	maximal	JJ	B-NP	O
carvedilol	carvedilol	NN	I-NP	O
and	and	CC	I-NP	O
digoxin	digoxin	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
is	be	VBZ	B-VP	O
now	now	RB	I-VP	O
being	be	VBG	I-VP	O
electively	electively	RB	I-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
right	right	JJ	B-NP	O
heart	heart	NN	I-NP	O
catheterization	catheterization	NN	I-NP	O
,	,	,	O	O
diuresis	diuresis	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
possible	possible	JJ	B-NP	O
repeat	repeat	NN	I-NP	O
cardioversion	cardioversion	NN	I-NP	O
versus	versus	IN	B-PP	O
amiodarone	amiodarone	NN	B-NP	O
challenge	challenge	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
completion	completion	NN	B-NP	O
of	of	IN	B-PP	O
his	his	PRP$	B-NP	O
transplant	transplant	NN	I-NP	O
evaluation	evaluation	NN	I-NP	O
.	.	.	O	O

PAST	PAST	NNP	B-NP	O
MEDICAL	MEDICAL	NNP	I-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Nonischemic	Nonischemic	JJ	B-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
,	,	,	O	O
EF	EF	NN	B-NP	B-protein
of	of	IN	B-PP	O
30	30	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
status	status	NN	I-NP	O
post	post	NN	I-NP	O
ICD	ICD	NN	I-NP	O
placement	placement	NN	I-NP	O
,	,	,	O	O
echo	echo	RB	B-ADVP	O
in	in	IN	B-PP	O
2/10	2/10	CD	B-NP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
EF	EF	NN	I-NP	O
of	of	IN	B-PP	O
30-35	30-35	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
dilated	dilated	JJ	I-NP	O
LV	LV	NN	I-NP	O
and	and	CC	O	O
anterior	anterior	JJ	B-NP	O
wall	wall	NN	I-NP	O
and	and	CC	O	O
septal	septal	JJ	B-NP	O
hypokinesis	hypokinesis	NN	I-NP	O
,	,	,	O	O
mild	mild	JJ	B-NP	O
mitral	mitral	JJ	I-NP	O
regurgitation	regurgitation	NN	I-NP	O
,	,	,	O	O
hypertension	hypertension	NN	B-NP	O
,	,	,	O	O
hyperlipidemia	hyperlipidemia	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
diabetes	diabete	NNS	B-NP	O
.	.	.	O	O

MEDICATIONS	MEDICATIONS	NNS	B-NP	O
AT	AT	NN	I-NP	O
HOME	HOME	NN	I-NP	O
:	:	:	O	O
Include	Include	VBP	B-VP	O
aspirin	aspirin	NN	B-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	JJ	B-ADJP	O
,	,	,	O	O
carvedilol	carvedilol	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
,	,	,	O	O
digoxin	digoxin	NN	B-NP	O
0.125	0.125	CD	I-NP	O
mg	mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
lisinopril	lisinopril	VBP	B-VP	O
20	20	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
Vytorin	Vytorin	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
metformin	metformin	NN	B-NP	O
500	500	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
glyburide	glyburide	NN	B-NP	O
2.5	2.5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Coumadin	Coumadin	NN	B-NP	O
,	,	,	O	O
iron	iron	NN	B-NP	O
sulfate	sulfate	NN	I-NP	O
325	325	CD	B-NP	O
mg	mg	NN	I-NP	O
daily	daily	JJ	B-ADJP	O
,	,	,	O	O
and	and	CC	O	O
magnesium	magnesium	NN	B-NP	O
gluconate	gluconate	NN	I-NP	O
500	500	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
ALLERGIES	ALLERGIES	NNPS	I-NP	O
:	:	:	O	O
He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
a	a	DT	B-NP	O
questionable	questionable	JJ	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
amiodarone	amiodarone	NN	B-NP	O
.	.	.	O	O

SOCIAL	SOCIAL	NNP	B-NP	O
HISTORY	HISTORY	NNP	I-NP	O
:	:	:	O	O
Lives	Lives	NNP	B-NP	O
on	on	IN	B-PP	O
Ence	Ence	NNP	B-NP	O
He	He	NNP	I-NP	O
does	do	VBZ	B-VP	O
not	not	RB	I-VP	O
drink	drink	VB	I-VP	O
,	,	,	I-VP	O
smoke	smoke	VB	I-VP	O
,	,	,	O	O
or	or	CC	O	O
use	use	VB	B-VP	O
any	any	DT	B-NP	O
other	other	JJ	I-NP	O
drugs	drug	NNS	I-NP	O
.	.	.	O	O

PHYSICAL	PHYSICAL	NN	B-NP	O
EXAM	EXAM	NN	I-NP	O
ON	ON	NN	I-NP	O
ADMISSION	ADMISSION	NN	I-NP	O
:	:	:	O	O
He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
afebrile	afebrile	JJ	B-ADJP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
heart	heart	NN	I-NP	O
rate	rate	NN	I-NP	O
of	of	IN	B-PP	O
106	106	CD	B-NP	O
in	in	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
blood	blood	NN	I-NP	O
pressure	pressure	NN	I-NP	O
is	be	VBZ	B-VP	O
102/78	102/78	CD	B-NP	O
and	and	CC	O	O
satting	satte	VBG	B-VP	O
98	98	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
room	room	NN	B-NP	O
air	air	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
no	no	DT	B-NP	O
distress	distress	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
JVP	JVP	NN	I-NP	B-protein
was	be	VBD	B-VP	O
approximately	approximately	RB	B-NP	O
12	12	CD	I-NP	O
cm	cm	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
right	right	JJ	I-NP	O
ventricular	ventricular	JJ	I-NP	O
heave	heave	NN	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
irregularly	irregularly	RB	B-ADJP	O
irregular	irregular	JJ	I-ADJP	O
with	with	IN	B-PP	O
an	an	DT	B-NP	O
S3	S3	NN	I-NP	B-protein
,	,	,	O	O
no	no	DT	B-NP	O
murmurs	murmur	NNS	I-NP	O
.	.	.	O	O

Chest	Chest	NNP	B-NP	O
is	be	VBZ	B-VP	O
clear	clear	JJ	B-ADJP	O
to	to	TO	B-PP	O
auscultation	auscultation	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
a	a	DT	B-NP	O
palpable	palpable	JJ	I-NP	O
pulsatile	pulsatile	JJ	I-NP	O
liver	liver	NN	I-NP	O
tip	tip	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
otherwise	otherwise	RB	B-ADVP	O
,	,	,	O	O
his	his	PRP$	B-NP	O
abdomen	abdoman	NNS	I-NP	O
was	be	VBD	B-VP	O
benign	benign	JJ	B-ADJP	O
.	.	.	O	O

He	He	PRP	B-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
lower	low	JJR	I-NP	O
extremity	extremity	NN	I-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
BY	BY	NN	I-NP	O
SYSTEM	SYSTEM	NN	I-NP	O
:	:	:	O	O
He	He	PRP	B-NP	B-DNA
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
62-year-old	62-year-old	JJ	I-NP	O
man	man	NN	I-NP	O
with	with	IN	B-PP	O
nonischemic	nonischemic	JJ	B-NP	O
cardiomyopathy	cardiomyopathy	NN	I-NP	O
,	,	,	O	O
EF	EF	NN	B-NP	O
30	30	CD	B-NP	O
%	%	NN	I-NP	O
,	,	,	O	O
awaiting	await	VBG	B-VP	O
transplant	transplant	NN	B-NP	O
who	who	WP	B-NP	O
is	be	VBZ	B-VP	O
now	now	RB	I-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
right	right	JJ	B-NP	O
heart	heart	NN	I-NP	O
catheterization	catheterization	NN	I-NP	O
and	and	CC	I-NP	O
diuresis	diuresis	NN	I-NP	O
for	for	IN	B-PP	O
volume	volume	NN	B-NP	O
overload	overload	NN	I-NP	O
and	and	CC	O	O
possible	possible	JJ	B-NP	O
amiodarone	amiodarone	NN	I-NP	O
challenge	challenge	NN	I-NP	O
versus	versus	IN	B-PP	O
cardioversion	cardioversion	NN	B-NP	O
,	,	,	O	O
rate	rate	NN	B-NP	O
and	and	CC	O	O
rhythm	rhythm	NN	B-NP	O
control	control	NN	I-NP	O
atrial	atrial	JJ	I-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

Cardiovascular	Cardiovascular	JJ	B-ADJP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
had	have	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
ischemia	ischemia	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
mildly	mildly	RB	B-NP	O
volume	volume	NN	I-NP	O
overloaded	overload	VBD	B-VP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
gently	gently	RB	I-VP	O
diuresed	diurese	VBN	I-VP	O
with	with	IN	B-PP	O
p.o.	p.o.	FW	B-NP	O
Lasix	Lasix	FW	I-NP	O
and	and	CC	O	O
eventually	eventually	RB	B-NP	O
b.i.d.	b.i.d.	FW	I-NP	O
p.o.	p.o.	FW	I-NP	O
torsemide	torsemide	NN	I-NP	O
at	at	IN	B-PP	O
60	60	CD	B-NP	O
mg	mg	NN	I-NP	O
b.i.d.	b.i.d.	RB	B-ADVP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
diuresed	diurese	VBN	I-VP	O
onto	onto	IN	B-PP	O
his	his	PRP$	B-NP	O
dry	dry	JJ	I-NP	O
weight	weight	NN	I-NP	O
of	of	IN	B-PP	O
70	70	CD	B-NP	O
kilograms	kilogram	NNS	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
exercise	exercise	NN	B-NP	O
stress	stress	NN	I-NP	O
testing	testing	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
able	able	JJ	B-ADJP	O
to	to	TO	B-VP	O
go	go	VB	I-VP	O
for	for	IN	B-PP	O
7	7	CD	B-NP	O
minutes	minute	NNS	I-NP	O
without	without	IN	B-PP	O
any	any	DT	B-NP	O
ischemic	ischemic	JJ	I-NP	O
changes	change	NNS	I-NP	O
.	.	.	O	O

His	His	PRP$	B-NP	O
rhythm	rhythm	NN	I-NP	O
rate	rate	NN	I-NP	O
was	be	VBD	B-VP	O
in	in	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
throughout	throughout	IN	B-ADVP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
peak	peak	JJ	B-NP	O
oxygen	oxygen	NN	I-NP	O
uptake	uptake	NN	I-NP	O
with	with	IN	B-PP	O
above	above	JJ	B-NP	O
is	be	VBZ	B-VP	O
anaerobic	anaerobic	JJ	B-NP	O
threshold	threshold	NN	I-NP	O
and	and	CC	O	O
his	his	PRP$	B-NP	O
peak	peak	JJ	I-NP	O
respiratory	respiratory	JJ	I-NP	O
exchange	exchange	NN	I-NP	O
ratio	ratio	NN	I-NP	O
was	be	VBD	B-VP	O
1.44	1.44	CD	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
underwent	undergo	VBD	B-VP	O
a	a	DT	B-NP	O
chest	chest	NN	I-NP	O
CT	CT	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
no	no	DT	B-NP	O
evidence	evidence	NN	I-NP	O
of	of	IN	B-PP	O
amiodarone	amiodarone	NN	B-NP	O
pneumonitis	pneumonitis	NN	I-NP	O
or	or	CC	O	O
interstitial	interstitial	JJ	B-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
then	then	RB	O	O
was	be	VBD	B-VP	O
subsequently	subsequently	RB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
amiodarone	amiodarone	NN	B-NP	O
challenge	challenge	NN	I-NP	O
in	in	IN	B-PP	O
attempts	attempt	NNS	B-NP	O
to	to	TO	B-PP	O
rhythm	rhythm	NN	B-NP	O
and	and	CC	I-NP	O
rate	rate	NN	I-NP	O
control	control	NN	I-NP	O
of	of	IN	B-PP	O
atrial	atrial	JJ	B-NP	O
fibrillation	fibrillation	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
resistant	resistant	JJ	B-ADJP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
amiodarone	amiodarone	NN	I-NP	O
in	in	IN	B-PP	O
terms	term	NNS	B-NP	O
of	of	IN	B-PP	O
rate	rate	NN	B-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
control	control	NN	I-NP	O
;	;	:	O	O
however	however	RB	B-ADVP	O
,	,	,	O	O
began	begin	VBD	B-VP	O
developing	develop	VBG	I-VP	O
elevated	elevated	JJ	B-NP	O
LFTs	LFT	NNS	I-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
amiodarone	amiodarone	NN	B-NP	O
hepatitis	hepatitis	NN	I-NP	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
a	a	DT	B-NP	O
persistent	persistent	JJ	I-NP	O
dry	dry	JJ	I-NP	O
cough	cough	NN	I-NP	O
concerning	concern	VBG	B-VP	O
for	for	IN	B-PP	O
amiodarone	amiodarone	NN	B-NP	O
pulmonary	pulmonary	JJ	I-NP	O
toxicity	toxicity	NN	I-NP	O
.	.	.	O	O

The	The	DT	B-NP	O
amiodarone	amiodarone	NN	I-NP	O
was	be	VBD	B-VP	O
stopped	stop	VBN	I-VP	O
and	and	CC	O	O
he	he	PRP	B-NP	O
was	be	VBD	B-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
dofetilide	dofetilide	NN	B-NP	O
at	at	IN	B-PP	O
125	125	CD	B-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
for	for	IN	B-PP	O
correcting	correct	VBG	B-VP	O
for	for	IN	B-PP	O
his	his	PRP$	B-NP	O
creatinine	creatinine	NN	I-NP	O
clearance	clearance	NN	I-NP	O
.	.	.	O	O

After	After	IN	B-PP	O
2	2	CD	B-NP	O
doses	dose	NNS	I-NP	O
of	of	IN	B-PP	O
dofetilide	dofetilide	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
converted	convert	VBD	B-VP	O
to	to	TO	B-PP	O
normal	normal	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
rate	rate	NN	B-NP	O
controlled	control	VBN	B-VP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
70s	70	NNS	I-NP	B-DNA
and	and	CC	I-NP	I-DNA
80s	80	NNS	I-NP	I-DNA
.	.	.	O	O

His	His	PRP$	B-NP	O
QTc	QTc	NN	I-NP	B-protein
was	be	VBD	B-VP	O
followed	follow	VBN	I-VP	O
twice	twice	RB	B-NP	O
a	a	DT	I-NP	O
day	day	NN	I-NP	O
and	and	CC	O	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
show	show	VB	I-VP	O
any	any	DT	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
prolongation	prolongation	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
was	be	VBD	B-VP	O
finally	finally	RB	I-VP	O
being	be	VBG	I-VP	O
discharged	discharge	VBN	I-VP	O
on	on	IN	B-PP	O
dofetilide	dofetilide	NN	B-NP	O
for	for	IN	B-PP	O
rate	rate	NN	B-NP	O
and	and	CC	I-NP	O
rhythm	rhythm	NN	I-NP	O
control	control	NN	I-NP	O
as	as	IN	B-SBAR	O
he	he	PRP	B-NP	O
is	be	VBZ	B-VP	O
now	now	RB	B-ADVP	O
in	in	IN	B-PP	O
normal	normal	JJ	B-NP	O
sinus	sinus	NN	I-NP	O
rhythm	rhythm	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
also	also	RB	I-VP	O
go	go	VB	I-VP	O
home	home	NN	B-NP	O
on	on	IN	B-PP	O
torsemide	torsemide	NN	B-NP	O
60	60	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
b.i.d.	b.i.d.	NN	I-NP	O
to	to	TO	B-VP	O
maintain	maintain	VB	I-VP	O
his	his	PRP$	B-NP	O
dry	dry	JJ	I-NP	O
weight	weight	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
instructed	instruct	VBN	I-VP	O
to	to	TO	I-VP	O
continue	continue	VB	I-VP	O
taking	take	VBG	I-VP	O
his	his	PRP$	B-NP	O
glyburide	glyburide	NN	I-NP	O
,	,	,	O	O
but	but	CC	O	O
not	not	RB	O	O
his	his	PRP$	B-NP	O
metformin	metformin	NN	I-NP	O
given	give	VBN	B-VP	O
his	his	PRP$	B-NP	O
poor	poor	JJ	I-NP	O
creatinine	creatinine	NN	I-NP	O
clearance	clearance	NN	I-NP	O
being	be	VBG	B-VP	O
discharged	discharge	VBN	I-VP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
creatinine	creatinine	NN	I-NP	O
of	of	IN	B-PP	O
1.6	1.6	CD	B-NP	O
and	and	CC	O	O
the	the	DT	B-NP	O
fact	fact	NN	I-NP	O
that	that	IN	B-SBAR	O
he	he	PRP	B-NP	O
is	be	VBZ	B-VP	O
on	on	IN	B-PP	O
metformin	metformin	NN	B-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
see	see	VB	I-VP	O
his	his	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
doctor	doctor	NN	I-NP	O
and	and	CC	O	O
will	will	MD	B-VP	O
either	either	RB	I-VP	O
likely	likely	RB	I-VP	O
be	be	VB	I-VP	O
started	start	VBN	I-VP	O
on	on	IN	B-PP	O
low-dose	low-dose	JJ	B-NP	B-protein
insulin	insulin	NN	I-NP	I-protein
or	or	CC	O	O
another	another	DT	B-NP	O
oral	oral	JJ	I-NP	O
hypoglycemic	hypoglycemic	JJ	I-NP	O
agent	agent	NN	I-NP	O
.	.	.	O	O

He	He	PRP	B-NP	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
up	up	RP	B-PRT	O
with	with	IN	B-PP	O
his	his	PRP$	B-NP	O
primary	primary	JJ	I-NP	O
care	care	NN	I-NP	O
doctor	doctor	NN	I-NP	O
and	and	CC	O	O
Dr.	Dr.	NNP	B-NP	O
Rosasco	Rosasco	NNP	I-NP	O
for	for	IN	B-PP	O
continued	continue	VBN	B-NP	O
transplant	transplant	NN	I-NP	O
evaluation	evaluation	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
Include	Include	VBP	B-VP	O
carvedilol	carvedilol	NN	B-NP	O
25	25	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
darbepoetin	darbepoetin	NN	B-NP	O
100	100	CD	I-NP	O
mcg	mcg	NN	I-NP	O
subcutaneous	subcutaneous	JJ	I-NP	O
q.	q.	NN	I-NP	O
week	week	NN	I-NP	O
,	,	,	O	O
digoxin	digoxin	NN	B-NP	O
0.125	0.125	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-PP	O
every	every	DT	B-NP	O
other	other	JJ	I-NP	O
day	day	NN	I-NP	O
,	,	,	O	O
dofetilide	dofetilide	NN	B-NP	O
125	125	CD	I-NP	O
mcg	mcg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Vytorin	Vytorin	NN	B-NP	O
one	one	CD	I-NP	O
tab	tab	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
iron	iron	NN	B-NP	O
sulfate	sulfate	NN	I-NP	O
325	325	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
glyburide	glyburide	NN	B-NP	O
5	5	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
potassium	potassium	NN	B-NP	O
40	40	CD	I-NP	O
mEq	mEq	NN	I-NP	O
p.o.	p.o.	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
lisinopril	lisinopril	NN	B-NP	O
10	10	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
Protonix	Protonix	NNP	B-NP	O
40	40	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
,	,	,	O	O
torsemide	torsemide	NN	B-NP	O
50	50	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	B-ADVP	O
b.i.d.	b.i.d.	FW	I-ADVP	O
,	,	,	O	O
Coumadin	Coumadin	NN	B-NP	O
2	2	CD	I-NP	O
mg	mg	NN	I-NP	O
p.o.	p.o.	FW	I-NP	O
q.p.m.	q.p.m.	NN	I-NP	O
FINAL	FINAL	NN	I-NP	O
ADDENDUM	ADDENDUM	NN	I-NP	O
:	:	:	O	O
The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
taking	take	VBG	I-VP	O
his	his	PRP$	B-NP	O
Coumadin	Coumadin	NN	I-NP	O
for	for	IN	B-PP	O
goal	goal	NN	B-NP	O
INR	INR	NN	I-NP	O
of	of	IN	B-PP	O
2-3	2-3	NN	B-NP	O
and	and	CC	O	O
follow	follow	VB	B-VP	O
up	up	RP	B-PRT	O
at	at	IN	B-PP	O
the	the	DT	B-NP	O
Vent	Vent	NNP	I-NP	O
Buffbo	Buffbo	NNP	I-NP	O
Medical	Medical	NNP	I-NP	O
Center	Center	NNP	I-NP	O
Coumadin	Coumadin	NNP	I-NP	O
Clinic	Clinic	NNP	I-NP	O
,	,	,	O	O
in	in	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
he	he	PRP	B-NP	O
received	receive	VBD	B-VP	O
one	one	CD	B-NP	O
unit	unit	NN	I-NP	O
of	of	IN	B-PP	O
packed	packed	JJ	B-NP	B-cell_type
red	red	JJ	I-NP	I-cell_type
blood	blood	NN	I-NP	I-cell_type
cells	cell	NNS	I-NP	I-cell_type
for	for	IN	B-PP	O
anemia	anemia	NN	B-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
disease	disease	NN	I-NP	O
and	and	CC	O	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
IV	IV	CD	B-NP	O
iron	iron	NN	I-NP	O
therapy	therapy	NN	I-NP	O
and	and	CC	O	O
will	will	MD	B-VP	O
continue	continue	VB	I-VP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
on	on	IN	B-PP	O
oral	oral	JJ	B-NP	O
iron	iron	NN	I-NP	O
replacement	replacement	NN	I-NP	O
.	.	.	O	O

eScription	eScription	NN	B-NP	O
document	document	NN	I-NP	O
:	:	:	O	O
8-2432312	8-2432312	CD	B-NP	O
EMSSten	EMSSten	NNP	I-NP	O
Tel	Tel	NNP	I-NP	O
Dictated	Dictated	NNP	I-NP	O
By	By	NNP	I-NP	O
:	:	:	O	O
GRABILL	GRABILL	NNP	B-NP	O
,	,	,	O	O
SERGIO	SERGIO	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
LOLL	LOLL	NNP	B-NP	O
,	,	,	O	O
JACINTO	JACINTO	NNP	B-NP	O
Dictation	Dictation	NNP	I-NP	O
ID	ID	NNP	I-NP	O
3325039	3325039	CD	I-NP	O
D	D	NNP	I-NP	O
:	:	:	O	O
3/9/06	3/9/06	CD	B-NP	O
T	T	NN	I-NP	O
:	:	:	O	O
3/9/06	3/9/06	CD	B-NP	O

